Galectin Therapeutics reported $24.18M in Cash and Equivalent for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Bristol Myers Squibb BMY:US $ 10750M 1619M
Galectin Therapeutics GALT:US $ 24.18M 7.43M
Gilead Sciences GILD:US $ 7000M 2704M
Idera Pharmaceuticals IDRA:US $ 24.48M 3.51M
Intercept Pharmaceuticals ICPT:US $ 58.02M 9.7M
Regulus Therapeutics RGLS:US $ 35.12M 18.78M
Vital Therapies VTL:US $ 88.08M 7.63M
YTE INCY:US $ 2435.38M 178.62M